{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:31:11Z","timestamp":1787671871363,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","award":["101080249"],"award-info":[{"award-number":["101080249"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ymgme.2026.109875","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:04:46Z","timestamp":1772557486000},"page":"109875","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The goal attainment scale in primary mitochondrial disease: Construct validity and lessons learned from a randomized controlled trial"],"prefix":"10.1016","volume":"148","author":[{"given":"Kristofoor E.","family":"Leeuwenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"IntHout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan T.","family":"Groothuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Cup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Smeitink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlien","family":"Mul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirian C.H.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2026.109875_bb0005","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1136\/jnnp-2012-303528","article-title":"The UK MRC Mitochondrial Disease Patient Cohort Study: clinical phenotypes associated with the m.3243A>G mutation--implications for diagnosis and management","volume":"84","author":"Nesbitt","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ymgme.2026.109875_bb0010","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/jimd.12281","article-title":"Moving towards clinical trials for mitochondrial diseases","volume":"44","author":"Pitceathly","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2026.109875_bb0015","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1212\/01.wnl.0000219759.72195.41","article-title":"Mitochondrial disease in adults: a scale to monitor progression and treatment","volume":"66","author":"Schaefer","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2026.109875_bb0020","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ymgme.2021.12.010","article-title":"Feasible and clinical relevant outcome measures for adults with mitochondrial disease","volume":"135","author":"Bergs","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.109875_bb0025","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s12874-019-0866-x","article-title":"Goal attainment scaling as an outcome measure in rare disease trials: a conceptual proposal for validation","volume":"19","author":"Gaasterland","year":"2019","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.ymgme.2026.109875_bb0030","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jval.2022.11.012","article-title":"Approaches to the assessment of clinical benefit of treatments for conditions that have heterogeneous symptoms and impacts: potential applications in rare disease","volume":"26","author":"Murray","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.ymgme.2026.109875_bb0035","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/BF01530764","article-title":"Goal attainment scaling: a general method for evaluating comprehensive community mental health programs","volume":"4","author":"Kiresuk","year":"1968","journal-title":"Community Ment. Health J."},{"key":"10.1016\/j.ymgme.2026.109875_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-063061","article-title":"Goal attainment scaling as an outcome measure for randomised controlled trials: a scoping review","volume":"12","author":"Logan","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.ymgme.2026.109875_bb0045","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/14713012231222309","article-title":"Setting individualised goals for people living with dementia and their family carers: a systematic review of goal-setting outcome measures and their psychometric properties","volume":"23","author":"Budgett","year":"2024","journal-title":"Dementia (London)"},{"key":"10.1016\/j.ymgme.2026.109875_bb0050","doi-asserted-by":"crossref","first-page":"904","DOI":"10.5014\/ajot.2010.08156","article-title":"Clinical utility of the combined use of the Canadian occupational performance measure and goal attainment scaling","volume":"64","author":"Doig","year":"2010","journal-title":"Am. J. Occup. Ther."},{"key":"10.1016\/j.ymgme.2026.109875_bb0055","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/1440-1630.12893","article-title":"Using PRPP-assessment for measuring change in everyday activities by home-based videos: an exploratory case series study in children with multiple disabilities","volume":"70","author":"Rothuizen-Lindenschot","year":"2023","journal-title":"Aust. Occup. Ther. J."},{"key":"10.1016\/j.ymgme.2026.109875_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2025.109087","article-title":"Goal attainment in PMM2-CDG: a new approach measuring meaningful clinical outcomes","volume":"145","author":"Verberkmoes","year":"2025","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.109875_bb0065","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-016-0205-4","article-title":"A systematic review to investigate the measurement properties of goal attainment scaling, towards use in drug trials","volume":"16","author":"Gaasterland","year":"2016","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.ymgme.2026.109875_bb0070","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ejca.2008.09.032","article-title":"Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European medicines Agency","volume":"45","author":"Bottomley","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ymgme.2026.109875_bb0075","author":"U.S. Food and Drug Administration (FDA)"},{"key":"10.1016\/j.ymgme.2026.109875_bb0080","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/cpt.1197","article-title":"The KHENERGY study: safety and efficacy of KH176 in mitochondrial m.3243A>G Spectrum disorders","volume":"105","author":"Janssen","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ymgme.2026.109875_bb0085","author":"Dekkers"},{"key":"10.1016\/j.ymgme.2026.109875_bb0090","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2340\/16501977-0041","article-title":"The international classification of functioning, disability and health (ICF): a unifying model for the conceptual description of the rehabilitation strategy","volume":"39","author":"Stucki","year":"2007","journal-title":"J. Rehabil. Med."},{"key":"10.1016\/j.ymgme.2026.109875_bb0095","series-title":"How to Use the ICF: A Practical Manual for Using the International Classification of Functioning, Disability and Health (ICF)","author":"World Health Organization","year":"2013"},{"key":"10.1016\/j.ymgme.2026.109875_bb0100","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/16501970510040263","article-title":"ICF linking rules: an update based on lessons learned","volume":"37","author":"Cieza","year":"2005","journal-title":"J. Rehabil. Med."},{"key":"10.1016\/j.ymgme.2026.109875_bb0105","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jpsychores.2017.05.007","article-title":"The assessment of fatigue: psychometric qualities and norms for the checklist individual strength","volume":"98","author":"Worm-Smeitink","year":"2017","journal-title":"J. Psychosom. Res."},{"key":"10.1016\/j.ymgme.2026.109875_bb0110","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med. Care"},{"key":"10.1016\/j.ymgme.2026.109875_bb0115","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/occmed\/kqv087","article-title":"Beck depression inventory","volume":"66","author":"Jackson-Koku","year":"2016","journal-title":"Occup. Med. (Lond.)"},{"key":"10.1016\/j.ymgme.2026.109875_bb0120","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2340\/16501977-2222","article-title":"Reliability of the 2- and 6-minute walk tests in neuromuscular diseases","volume":"49","author":"Knak","year":"2017","journal-title":"J. Rehabil. Med."},{"key":"10.1016\/j.ymgme.2026.109875_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.csda.2024.108013","article-title":"Multivariate ordinal regression for multiple repeated measurements","volume":"199","author":"Vana-G\u00fcr","year":"2024","journal-title":"Comput. Stat. Data Anal."},{"key":"10.1016\/j.ymgme.2026.109875_bb0130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.apmr.2015.08.424","article-title":"Proposed criteria for appraising goal attainment scales used as outcome measures in rehabilitation research","volume":"97","author":"Krasny-Pacini","year":"2016","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"10.1016\/j.ymgme.2026.109875_bb0135","series-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2025"},{"key":"10.1016\/j.ymgme.2026.109875_bb0140","series-title":"Rstudio: Integrated Development Environment for R","author":"Posit Team","year":"2025"},{"key":"10.1016\/j.ymgme.2026.109875_bb0145","series-title":"mvordflex: Multivariate Ordinal Regression Models - Extension to three Dimensional Panel Data","author":"Hirk","year":"2024"},{"key":"10.1016\/j.ymgme.2026.109875_bb0150","series-title":"Boot: Bootstrap R (S-plus) Functions","author":"Angelo","year":"2024"},{"key":"10.1016\/j.ymgme.2026.109875_bb0155","series-title":"Bootstrap Methods and their Application","author":"Davison","year":"1997"},{"key":"10.1016\/j.ymgme.2026.109875_bb0160","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200229","article-title":"Characterization of fatigue in primary mitochondrial myopathies: findings from a qualitative interview study","volume":"14","author":"Karaa","year":"2024","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.ymgme.2026.109875_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2025.109153","article-title":"Qualitative study of fatigue in adults with primary mitochondrial disease: development of the PROMIS fatigue mitochondrial disease short form","volume":"145","author":"Clifford","year":"2025","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.109875_bb0170","author":"National Multiple Sclerosis Society"},{"key":"10.1016\/j.ymgme.2026.109875_bb0175","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12311-025-01932-w","article-title":"The goal attainment scale in spinocerebellar Ataxia type 3: exploration of feasibility and content validity","volume":"24","author":"Leeuwenberg","year":"2025","journal-title":"Cerebellum"},{"key":"10.1016\/j.ymgme.2026.109875_bb0180","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1177\/0269215508101744","article-title":"The practical use of goal attainment scaling for people with acquired brain injury who receive cognitive rehabilitation","volume":"23","author":"Bouwens","year":"2009","journal-title":"Clin. Rehabil."},{"key":"10.1016\/j.ymgme.2026.109875_bb0185","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s41687-023-00615-6","article-title":"Feasibility of goal attainment scaling as a patient-reported outcome measure for older patients in primary care","volume":"7","author":"Stolee","year":"2023","journal-title":"J. Patient Rep. Outcomes"},{"key":"10.1016\/j.ymgme.2026.109875_bb0190","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/13638490500235581","article-title":"A comparison of goal attainment scaling and the Canadian occupational performance measure for paediatric rehabilitation research","volume":"9","author":"Cusick","year":"2006","journal-title":"Pediatr. Rehabil."},{"key":"10.1016\/j.ymgme.2026.109875_bb0195","unstructured":"European Medicines Agency (EMA), ISG Meeting 2025: Patient Experience Data in Medicines Development and Regulatory Decision-Making. https:\/\/www.ema.europa.eu\/en\/documents\/presentation\/presentation-patient-experience-data-development-programs-regulatory-decision-making-r-gonzalez-quevedo-ema_en.pdf. Accessed 17-10-2025. 2026."},{"key":"10.1016\/j.ymgme.2026.109875_bb0200","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/0269215508101741","article-title":"Writing SMART rehabilitation goals and achieving goal attainment scaling: a practical guide","volume":"23","author":"Bovend\u2019Eerdt","year":"2009","journal-title":"Clin. Rehabil."},{"key":"10.1016\/j.ymgme.2026.109875_bb0205","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1177\/0269215508101742","article-title":"Goal attainment scaling (GAS) in rehabilitation: a practical guide","volume":"23","author":"Turner-Stokes","year":"2009","journal-title":"Clin. Rehabil."},{"key":"10.1016\/j.ymgme.2026.109875_bb0210","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s41687-024-00704-0","article-title":"Training healthcare professionals to administer goal attainment scaling as an outcome measure","volume":"8","author":"Logan","year":"2024","journal-title":"J. Patient Rep. Outcomes"},{"key":"10.1016\/j.ymgme.2026.109875_bb0215","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s41687-020-00196-8","article-title":"The responsiveness of goal attainment scaling using just one goal in controlled clinical trials: an exploratory analysis","volume":"4","author":"McGarrigle","year":"2020","journal-title":"J. Patient Rep. Outcomes"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226001587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226001587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:01:37Z","timestamp":1787670097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719226001587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1096719226001587"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.109875","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The goal attainment scale in primary mitochondrial disease: Construct validity and lessons learned from a randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.109875","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109875"}}